Recently, this antibody exhibited therapeutic effects in colorectal cancer by suppressing tumor growth, reducing immunosuppressive M2-like tumor-associated macrophages, and maintaining T cell anti-tumor activity within the tumor microenvironment through AQP3 targeting [194]. This evidence concerns the gene AQP3 and neoplasm.